Global Anticoagulants Market 2023-2029

April 2023 | 71 pages | ID: G7A10C1223B2EN
Gen Consulting Company

Abstracts

Anticoagulants are drugs that prevent the formation of blood clots or dissolve existing blood clots in the body. They work by interfering with the blood clotting process, which involves a complex series of chemical reactions that result in the formation of a clot. Anticoagulants are used to treat and prevent blood clots, which can lead to serious health problems such as stroke, heart attack, and pulmonary embolism. They are also used in some medical procedures, such as surgery, to prevent the formation of blood clots. The global anticoagulants market size is projected to grow by USD 12.2 billion from 2023 to 2029, registering a CAGR of 6.7 percent, according to the latest market data.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global anticoagulants market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the drug class, disease indication, route of administration, distribution channel, and region. The global market for anticoagulants can be segmented by drug class: heparin and low-molecular weight heparin (LMWH), novel oral anticoagulants (NOACs), vitamin K antagonists (VKAs). The NOACs segment held the largest revenue share in 2022. Anticoagulants market is further segmented by disease indication: atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, others. Among these, the atrial fibrillation/myocardial infarction (heart attack) segment was accounted for the highest revenue generator in 2022. Based on route of administration, the anticoagulants market is segmented into: injectable, oral, others. The oral segment captured the largest share of the market in 2022. On the basis of distribution channel, the anticoagulants market also can be divided into: hospitals, online pharmacies, pharmacies. Anticoagulants market by region is categorized into: Asia-Pacific, Europe, North America, Rest of the World (RoW). North America held the largest revenue share in 2022.

Market Segmentation

By drug class: heparin and low-molecular weight heparin (LMWH), novel oral anticoagulants (NOACs), vitamin K antagonists (VKAs)

By disease indication: atrial fibrillation/myocardial infarction (heart attack), deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, others

By route of administration: injectable, oral, others

By distribution channel: hospitals, online pharmacies, pharmacies

By region: Asia-Pacific, Europe, North America, Rest of the World (RoW)

The report has also analysed the competitive landscape of the global anticoagulants market with some of the key players being Alexion Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited, Bayer AG, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., GSK plc (formerly GlaxoSmithKline plc), Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report

• To analyze and forecast the market size of the global anticoagulants market.
• To classify and forecast the global anticoagulants market based on drug class, disease indication, route of administration, distribution channel, region.
• To identify drivers and challenges for the global anticoagulants market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global anticoagulants market.
• To identify and analyze the profile of leading players operating in the global anticoagulants market.

Why Choose This Report

• Gain a reliable outlook of the global anticoagulants market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY DRUG CLASS

Heparin and low-molecular weight heparin (LMWH)
Novel oral anticoagulants (NOACs)
Vitamin K antagonists (VKAs)

PART 6. MARKET BREAKDOWN BY DISEASE INDICATION

Atrial fibrillation/myocardial infarction (heart attack)
Deep vein thrombosis (DVT)
Pulmonary embolism (PE)
Stroke
Others

PART 7. MARKET BREAKDOWN BY ROUTE OF ADMINISTRATION

Injectable
Oral
Others

PART 8. MARKET BREAKDOWN BY DISTRIBUTION CHANNEL

Hospitals
Online pharmacies
Pharmacies

PART 9. MARKET BREAKDOWN BY REGION

Asia-Pacific
Europe
North America
Rest of the World (RoW)

PART 10. KEY COMPANIES

Alexion Pharmaceuticals, Inc.
Aspen Pharmacare Holdings Limited
Bayer AG
Boehringer Ingelheim Pharmaceuticals Inc.
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Ltd.
GSK plc (formerly GlaxoSmithKline plc)
Johnson & Johnson
LEO Pharma A/S
Novartis AG
Pfizer Inc.
Sanofi S.A.
DISCLAIMER